+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Future of Dyskinesia R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

  • ID: 4749282
  • Report
  • 130 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • A2M Pharma GmbH
  • Cadent Therapeutics
  • Clevexel Pharma SAS
  • H. Lundbeck AS
  • MentiNova Inc
  • Neurolixis Inc
  • MORE
The global demand for Dyskinesia treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Dyskinesia pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Dyskinesia pipeline companies from advancing their products into Phase 3 or Phase 4.

Dyskinesia Report Description

The 2019 pipeline study on Dyskinesia pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Dyskinesia pipeline compounds.

The Dyskinesia pipeline guide presents information on all active drugs currently being developed for Dyskinesia. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Dyskinesia pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Dyskinesia drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Dyskinesia product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Dyskinesia pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

The publisher has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Dyskinesia pipeline report includes
  • An overview of Dyskinesia disease including symptoms, causes, diagnosis and available treatment options is provided.
  • Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
  • Phase wise count of Dyskinesia pipeline
  • Company wise list of Dyskinesia pipeline
  • Mechanism of Action wise Dyskinesia pipeline
For each pipeline candidate, the following details are provided:
  • Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
  • Current status of development
  • Drug overview
  • Mechanism of Action
  • Pre-clinical and Clinical Trials/Results
  • Company Overview and Recent Developments
Reasons to Buy
  • The report is designed to help industry executives promote the success and continued growth of their organizations
  • Get clear understanding of the entire Dyskinesia pipeline, with details on active projects
  • Stay ahead of the competition through comprehensive knowledge of Dyskinesia pipeline progress
  • Get in detail information of each product with updated information on each project along with key milestones
  • Gain clear insights into companies participating in Dyskinesia pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
The report will be delivered in 2 working days.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • A2M Pharma GmbH
  • Cadent Therapeutics
  • Clevexel Pharma SAS
  • H. Lundbeck AS
  • MentiNova Inc
  • Neurolixis Inc
  • MORE
1.1 List of Tables
1.2 List of Figures

2. Global Dyskinesia Pipeline Overview
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology

3. Executive Summary
3.1 Dyskinesia Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
3.2.1 Pre-clinical
3.2.2 Discovery
3.2.3 Phase 1
3.2.4Phase 2
3.3 Pipeline Drugs in Advanced Stage of Development
3.3.1 Phase 3
3.3.2 Pre-registration
3.4 Companies involved in Dyskinesia pipeline, H1- 2019
3.5 Mechanism of Action wise Dyskinesia Pipeline Candidates

4 A2M Pharma GmbH Dyskinesia Pipeline Details
4.1 A2M Pharma GmbH Business Profile
4.2 A2M Pharma GmbH Dyskinesia Drug Details
4.3 Drug Snapshot
4.3.1 Originator
4.3.2 Collaborator/Co-Developer
4.3.3 Route of Administration
4.3.4 Orphan Drug/Fast Track/Special Designation
4.3.5 Geography
4.3.6 Type of Molecular Entity
4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5 Addex Therapeutics Ltd Dyskinesia Pipeline Details
5.1 Addex Therapeutics Ltd Business Profile
5.2 Addex Therapeutics Ltd Dyskinesia Drug Details
5.3 Drug Snapshot
5.3.1 Originator
5.3.2 Collaborator/Co-Developer
5.3.3 Route of Administration
5.3.4 Orphan Drug/Fast Track/Special Designation
5.3.5 Geography
5.3.6 Type of Molecular Entity
5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6 Amarantus Bioscience Holdings Inc Dyskinesia Pipeline Details
6.1 Amarantus Bioscience Holdings Inc Business Profile
6.2 Amarantus Bioscience Holdings Inc Dyskinesia Drug Details
6.3 Drug Snapshot
6.3.1 Originator
6.3.2 Collaborator/Co-Developer
6.3.3 Route of Administration
6.3.4 Orphan Drug/Fast Track/Special Designation
6.3.5 Geography
6.3.6 Type of Molecular Entity
6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7 Astraea Therapeutics LLC Dyskinesia Pipeline Details
7.1 Astraea Therapeutics LLC Business Profile
7.2 Astraea Therapeutics LLC Dyskinesia Drug Details
7.3 Drug Snapshot
7.3.1 Originator
7.3.2 Collaborator/Co-Developer
7.3.3 Route of Administration
7.3.4 Orphan Drug/Fast Track/Special Designation
7.3.5 Geography
7.3.6 Type of Molecular Entity
7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8 Avanir Pharmaceuticals Inc Dyskinesia Pipeline Details
8.1 Avanir Pharmaceuticals Inc Business Profile
8.2 Avanir Pharmaceuticals Inc Dyskinesia Drug Details
8.3 Drug Snapshot
8.3.1 Originator
8.3.2 Collaborator/Co-Developer
8.3.3 Route of Administration
8.3.4 Orphan Drug/Fast Track/Special Designation
8.3.5 Geography
8.3.6 Type of Molecular Entity
8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9 Cadent Therapeutics Dyskinesia Pipeline Details
9.1 Cadent Therapeutics Business Profile
9.2 Cadent Therapeutics Dyskinesia Drug Details
9.3 Drug Snapshot
9.3.1 Originator
9.3.2 Collaborator/Co-Developer
9.3.3 Route of Administration
9.3.4 Orphan Drug/Fast Track/Special Designation
9.3.5 Geography
9.3.6 Type of Molecular Entity
9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments

10 Cavion LLC Dyskinesia Pipeline Details
10.1 Cavion LLC Business Profile
10.2 Cavion LLC Dyskinesia Drug Details
10.3 Drug Snapshot
10.3.1 Originator
10.3.2 Collaborator/Co-Developer
10.3.3 Route of Administration
10.3.4 Orphan Drug/Fast Track/Special Designation
10.3.5 Geography
10.3.6 Type of Molecular Entity
10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments

11 Cerevance Inc Dyskinesia Pipeline Details
11.1 Cerevance Inc Business Profile
11.2 Cerevance Inc Dyskinesia Drug Details
11.3 Drug Snapshot
11.3.1 Originator
11.3.2 Collaborator/Co-Developer
11.3.3 Route of Administration
11.3.4 Orphan Drug/Fast Track/Special Designation
11.3.5 Geography
11.3.6 Type of Molecular Entity
11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments

12 Clevexel Pharma SAS Dyskinesia Pipeline Details
12.1 Clevexel Pharma SAS Business Profile
12.2 Clevexel Pharma SAS Dyskinesia Drug Details
12.3 Drug Snapshot
12.3.1 Originator
12.3.2 Collaborator/Co-Developer
12.3.3 Route of Administration
12.3.4 Orphan Drug/Fast Track/Special Designation
12.3.5 Geography
12.3.6 Type of Molecular Entity
12.3.7 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments

13 Contera Pharma ApS Dyskinesia Pipeline Details
13.1 Contera Pharma ApS Business Profile
13.2 Contera Pharma ApS Dyskinesia Drug Details
13.3 Drug Snapshot
13.3.1 Originator
13.3.2 Collaborator/Co-Developer
13.3.3 Route of Administration
13.3.4 Orphan Drug/Fast Track/Special Designation
13.3.5 Geography
13.3.6 Type of Molecular Entity
13.3.7 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments

14 EpiVax Inc Dyskinesia Pipeline Details
14.1 EpiVax Inc Business Profile
14.2 EpiVax Inc Dyskinesia Drug Details
14.3 Drug Snapshot
14.3.1 Originator
14.3.2 Collaborator/Co-Developer
14.3.3 Route of Administration
14.3.4 Orphan Drug/Fast Track/Special Designation
14.3.5 Geography
14.3.6 Type of Molecular Entity
14.3.7 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments

15 H. Lundbeck AS Dyskinesia Pipeline Details
15.1 H. Lundbeck AS Business Profile
15.2 H. Lundbeck AS Dyskinesia Drug Details
15.3 Drug Snapshot
15.3.1 Originator
15.3.2 Collaborator/Co-Developer
15.3.3 Route of Administration
15.3.4 Orphan Drug/Fast Track/Special Designation
15.3.5 Geography
15.3.6 Type of Molecular Entity
15.3.7 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments

16 Hua Medicine (Shanghai) Ltd Dyskinesia Pipeline Details
16.1 Hua Medicine (Shanghai) Ltd Business Profile
16.2 Hua Medicine (Shanghai) Ltd Dyskinesia Drug Details
16.3 Drug Snapshot
16.3.1 Originator
16.3.2 Collaborator/Co-Developer
16.3.3 Route of Administration
16.3.4 Orphan Drug/Fast Track/Special Designation
16.3.5 Geography
16.3.6 Type of Molecular Entity
16.3.7 Current Status
16.4 Drug Overview
16.5 Drug Mechanism of Action
16.6 Clinical/Pre-clinical Trial Details
16.7 Latest Drug Developments

17 India Globalization Capital Inc Dyskinesia Pipeline Details
17.1 India Globalization Capital Inc Business Profile
17.2 India Globalization Capital Inc Dyskinesia Drug Details
17.3 Drug Snapshot
17.3.1 Originator
17.3.2 Collaborator/Co-Developer
17.3.3 Route of Administration
17.3.4 Orphan Drug/Fast Track/Special Designation
17.3.5 Geography
17.3.6 Type of Molecular Entity
17.3.7 Current Status
17.4 Drug Overview
17.5 Drug Mechanism of Action
17.6 Clinical/Pre-clinical Trial Details
17.7 Latest Drug Developments

18 IRLAB Therapeutics AB Dyskinesia Pipeline Details
18.1 IRLAB Therapeutics AB Business Profile
18.2 IRLAB Therapeutics AB Dyskinesia Drug Details
18.3 Drug Snapshot
18.3.1 Originator
18.3.2 Collaborator/Co-Developer
18.3.3 Route of Administration
18.3.4 Orphan Drug/Fast Track/Special Designation
18.3.5 Geography
18.3.6 Type of Molecular Entity
18.3.7 Current Status
18.4 Drug Overview
18.5 Drug Mechanism of Action
18.6 Clinical/Pre-clinical Trial Details
18.7 Latest Drug Developments

19 Junaxo Inc Dyskinesia Pipeline Details
19.1 Junaxo Inc Business Profile
19.2 Junaxo Inc Dyskinesia Drug Details
19.3 Drug Snapshot
19.3.1 Originator
19.3.2 Collaborator/Co-Developer
19.3.3 Route of Administration
19.3.4 Orphan Drug/Fast Track/Special Designation
19.3.5 Geography
19.3.6 Type of Molecular Entity
19.3.7 Current Status
19.4 Drug Overview
19.5 Drug Mechanism of Action
19.6 Clinical/Pre-clinical Trial Details
19.7 Latest Drug Developments

20 Melior Pharmaceuticals II LLC Dyskinesia Pipeline Details
20.1 Melior Pharmaceuticals II LLC Business Profile
20.2 Melior Pharmaceuticals II LLC Dyskinesia Drug Details
20.3 Drug Snapshot
20.3.1 Originator
20.3.2 Collaborator/Co-Developer
20.3.3 Route of Administration
20.3.4 Orphan Drug/Fast Track/Special Designation
20.3.5 Geography
20.3.6 Type of Molecular Entity
20.3.7 Current Status
20.4 Drug Overview
20.5 Drug Mechanism of Action
20.6 Clinical/Pre-clinical Trial Details
20.7 Latest Drug Developments

21 MentiNova Inc Dyskinesia Pipeline Details
21.1 MentiNova Inc Business Profile
21.2 MentiNova Inc Dyskinesia Drug Details
21.3 Drug Snapshot
21.3.1 Originator
21.3.2 Collaborator/Co-Developer
21.3.3 Route of Administration
21.3.4 Orphan Drug/Fast Track/Special Designation
21.3.5 Geography
21.3.6 Type of Molecular Entity
21.3.7 Current Status
21.4 Drug Overview
21.5 Drug Mechanism of Action
21.6 Clinical/Pre-clinical Trial Details
21.7 Latest Drug Developments

22 Merz Pharma GmbH & Co. KgaA Dyskinesia Pipeline Details
22.1 Merz Pharma GmbH & Co. KgaA Business Profile
22.2 Merz Pharma GmbH & Co. KgaA Dyskinesia Drug Details
22.3 Drug Snapshot
22.3.1 Originator
22.3.2 Collaborator/Co-Developer
22.3.3 Route of Administration
22.3.4 Orphan Drug/Fast Track/Special Designation
22.3.5 Geography
22.3.6 Type of Molecular Entity
22.3.7 Current Status
22.4 Drug Overview
22.5 Drug Mechanism of Action
22.6 Clinical/Pre-clinical Trial Details
22.7 Latest Drug Developments

23 MitoDys Therapeutics Ltd Dyskinesia Pipeline Details
23.1 MitoDys Therapeutics Ltd Business Profile
23.2 MitoDys Therapeutics Ltd Dyskinesia Drug Details
23.3 Drug Snapshot
23.3.1 Originator
23.3.2 Collaborator/Co-Developer
23.3.3 Route of Administration
23.3.4 Orphan Drug/Fast Track/Special Designation
23.3.5 Geography
23.3.6 Type of Molecular Entity
23.3.7 Current Status
23.4 Drug Overview
23.5 Drug Mechanism of Action
23.6 Clinical/Pre-clinical Trial Details
23.7 Latest Drug Developments

24 Mylan NV Dyskinesia Pipeline Details
24.1 Mylan NV Business Profile
24.2 Mylan NV Dyskinesia Drug Details
24.3 Drug Snapshot
24.3.1 Originator
24.3.2 Collaborator/Co-Developer
24.3.3 Route of Administration
24.3.4 Orphan Drug/Fast Track/Special Designation
24.3.5 Geography
24.3.6 Type of Molecular Entity
24.3.7 Current Status
24.4 Drug Overview
24.5 Drug Mechanism of Action
24.6 Clinical/Pre-clinical Trial Details
24.7 Latest Drug Developments

25 Neurim Pharmaceuticals Ltd Dyskinesia Pipeline Details
25.1 Neurim Pharmaceuticals Ltd Business Profile
25.2 Neurim Pharmaceuticals Ltd Dyskinesia Drug Details
25.3 Drug Snapshot
25.3.1 Originator
25.3.2 Collaborator/Co-Developer
25.3.3 Route of Administration
25.3.4 Orphan Drug/Fast Track/Special Designation
25.3.5 Geography
25.3.6 Type of Molecular Entity
25.3.7 Current Status
25.4 Drug Overview
25.5 Drug Mechanism of Action
25.6 Clinical/Pre-clinical Trial Details
25.7 Latest Drug Developments

26 Neurocrine Biosciences Inc Dyskinesia Pipeline Details
26.1 Neurocrine Biosciences Inc Business Profile
26.2 Neurocrine Biosciences Inc Dyskinesia Drug Details
26.3 Drug Snapshot
26.3.1 Originator
26.3.2 Collaborator/Co-Developer
26.3.3 Route of Administration
26.3.4 Orphan Drug/Fast Track/Special Designation
26.3.5 Geography
26.3.6 Type of Molecular Entity
26.3.7 Current Status
26.4 Drug Overview
26.5 Drug Mechanism of Action
26.6 Clinical/Pre-clinical Trial Details
26.7 Latest Drug Developments

27 Neurolixis Inc Dyskinesia Pipeline Details
27.1 Neurolixis Inc Business Profile
27.2 Neurolixis Inc Dyskinesia Drug Details
27.3 Drug Snapshot
27.3.1 Originator
27.3.2 Collaborator/Co-Developer
27.3.3 Route of Administration
27.3.4 Orphan Drug/Fast Track/Special Designation
27.3.5 Geography
27.3.6 Type of Molecular Entity
27.3.7 Current Status
27.4 Drug Overview
27.5 Drug Mechanism of Action
27.6 Clinical/Pre-clinical Trial Details
27.7 Latest Drug Developments

28 Newron Pharmaceuticals SpA Dyskinesia Pipeline Details
28.1 Newron Pharmaceuticals SpA Business Profile
28.2 Newron Pharmaceuticals SpA Dyskinesia Drug Details
28.3 Drug Snapshot
28.3.1 Originator
28.3.2 Collaborator/Co-Developer
28.3.3 Route of Administration
28.3.4 Orphan Drug/Fast Track/Special Designation
28.3.5 Geography
28.3.6 Type of Molecular Entity
28.3.7 Current Status
28.4 Drug Overview
28.5 Drug Mechanism of Action
28.6 Clinical/Pre-clinical Trial Details
28.7 Latest Drug Developments

29 Phenomenome Discoveries Inc Dyskinesia Pipeline Details
29.1 Phenomenome Discoveries Inc Business Profile
29.2 Phenomenome Discoveries Inc Dyskinesia Drug Details
29.3 Drug Snapshot
29.3.1 Originator
29.3.2 Collaborator/Co-Developer
29.3.3 Route of Administration
29.3.4 Orphan Drug/Fast Track/Special Designation
29.3.5 Geography
29.3.6 Type of Molecular Entity
29.3.7 Current Status
29.4 Drug Overview
29.5 Drug Mechanism of Action
29.6 Clinical/Pre-clinical Trial Details
29.7 Latest Drug Developments

30 PolyCore Therapeutics LLC Dyskinesia Pipeline Details
30.1 PolyCore Therapeutics LLC Business Profile
30.2 PolyCore Therapeutics LLC Dyskinesia Drug Details
30.3 Drug Snapshot
30.3.1 Originator
30.3.2 Collaborator/Co-Developer
30.3.3 Route of Administration
30.3.4 Orphan Drug/Fast Track/Special Designation
30.3.5 Geography
30.3.6 Type of Molecular Entity
30.3.7 Current Status
30.4 Drug Overview
30.5 Drug Mechanism of Action
30.6 Clinical/Pre-clinical Trial Details
30.7 Latest Drug Developments

31 Revance Therapeutics Inc Dyskinesia Pipeline Details
31.1 Revance Therapeutics Inc Business Profile
31.2 Revance Therapeutics Inc Dyskinesia Drug Details
31.3 Drug Snapshot
31.3.1 Originator
31.3.2 Collaborator/Co-Developer
31.3.3 Route of Administration
31.3.4 Orphan Drug/Fast Track/Special Designation
31.3.5 Geography
31.3.6 Type of Molecular Entity
31.3.7 Current Status
31.4 Drug Overview
31.5 Drug Mechanism of Action
31.6 Clinical/Pre-clinical Trial Details
31.7 Latest Drug Developments

32 Sage Therapeutics Inc Dyskinesia Pipeline Details
32.1 Sage Therapeutics Inc Business Profile
32.2 Sage Therapeutics Inc Dyskinesia Drug Details
32.3 Drug Snapshot
32.3.1 Originator
32.3.2 Collaborator/Co-Developer
32.3.3 Route of Administration
32.3.4 Orphan Drug/Fast Track/Special Designation
32.3.5 Geography
32.3.6 Type of Molecular Entity
32.3.7 Current Status
32.4 Drug Overview
32.5 Drug Mechanism of Action
32.6 Clinical/Pre-clinical Trial Details
32.7 Latest Drug Developments

33 SalubRx Therapeutics Inc Dyskinesia Pipeline Details
33.1 SalubRx Therapeutics Inc Business Profile
33.2 SalubRx Therapeutics Inc Dyskinesia Drug Details
33.3 Drug Snapshot
33.3.1 Originator
33.3.2 Collaborator/Co-Developer
33.3.3 Route of Administration
33.3.4 Orphan Drug/Fast Track/Special Designation
33.3.5 Geography
33.3.6 Type of Molecular Entity
33.3.7 Current Status
33.4 Drug Overview
33.5 Drug Mechanism of Action
33.6 Clinical/Pre-clinical Trial Details
33.7 Latest Drug Developments

34 SOM Biotech SL Dyskinesia Pipeline Details
34.1 SOM Biotech SL Business Profile
34.2 SOM Biotech SL Dyskinesia Drug Details
34.3 Drug Snapshot
34.3.1 Originator
34.3.2 Collaborator/Co-Developer
34.3.3 Route of Administration
34.3.4 Orphan Drug/Fast Track/Special Designation
34.3.5 Geography
34.3.6 Type of Molecular Entity
34.3.7 Current Status
34.4 Drug Overview
34.5 Drug Mechanism of Action
34.6 Clinical/Pre-clinical Trial Details
34.7 Latest Drug Developments

35 Ultragenyx Pharmaceutical Inc Dyskinesia Pipeline Details
35.1 Ultragenyx Pharmaceutical Inc Business Profile
35.2 Ultragenyx Pharmaceutical Inc Dyskinesia Drug Details
35.3 Drug Snapshot
35.3.1 Originator
35.3.2 Collaborator/Co-Developer
35.3.3 Route of Administration
35.3.4 Orphan Drug/Fast Track/Special Designation
35.3.5 Geography
35.3.6 Type of Molecular Entity
35.3.7 Current Status
35.4 Drug Overview
35.5 Drug Mechanism of Action
35.6 Clinical/Pre-clinical Trial Details
35.7 Latest Drug Developments

36. Latest Dyskinesia Drug Pipeline Developments, 2019

37. Appendix
37.1 About Us
37.2 Sources and Methodology
37.3 Contact Information
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • A2M Pharma GmbH
  • Addex Therapeutics Ltd
  • Amarantus Bioscience Holdings Inc
  • Astraea Therapeutics LLC
  • Avanir Pharmaceuticals Inc
  • Cadent Therapeutics
  • Cavion LLC
  • Cerevance Inc
  • Clevexel Pharma SAS
  • Contera Pharma ApS
  • EpiVax Inc
  • H. Lundbeck AS
  • Hua Medicine (Shanghai) Ltd
  • India Globalization Capital Inc
  • IRLAB Therapeutics AB
  • Junaxo Inc
  • Melior Pharmaceuticals II LLC
  • MentiNova Inc
  • Merz Pharma GmbH & Co. KgaA
  • MitoDys Therapeutics Ltd
  • Mylan NV
  • Neurim Pharmaceuticals Ltd
  • Neurocrine Biosciences Inc
  • Neurolixis Inc
  • Newron Pharmaceuticals SpA
  • Phenomenome Discoveries Inc
  • PolyCore Therapeutics LLC
  • Revance Therapeutics Inc
  • Sage Therapeutics Inc
  • SalubRx Therapeutics Inc
  • SOM Biotech SL
  • Ultragenyx Pharmaceutical Inc
Note: Product cover images may vary from those shown
Adroll
adroll